Conversational AI and AI powered video bots for health education
On March 19th 2024 the lawyers of KIELTYKA GLADKOWSKI took part in the workshop devoted to the use of AI in patient engagement.
The workshop focused on the utilization of artificial intelligence (AI) in patient care and was led by Lawrence Byrd, Senior Director of Communications APIs at Vonage. The Vonage company is a global cloud communication leader providing Apps and APIs (such as AI, Video, Voice, SMS, UC, and more) and is a prominent supplier of embedded video for hundreds of global Telehealth innovators. Vonage also assists businesses in stimulating their digital transformation.
The sale of a new drug or medical device and clinical trials is a process between two opposing interest groups. On the one hand, it is about patient protection and the safety of the pharmaceutical market. On the other hand, it is about creating a legal environment that will accelerate the creation of new drugs.
Both goals are important. It is important to create the right legal balance. The balance between patient protection and facilitation of modern medicines and medical devices makes Europe attractive for locating new innovations in technology and creating new medicines and medical devices.
Placing legal priorities in creating law is a political compromise between the speed of producing a new drug and blocking innovation justified by patient safety.
The attractiveness of Europe for the pharmaceutical business compared to other global markets depends on the proper placement of priorities.
Conducting a clinical trial does not relieve the investigator and sponsor from civil liability arising from the clinical trial, under Polish law provisions. The sponsor and the investigator are civilly liable for any damage caused to a clinical trial participant resulting from their actions or omissions. The above general principles of liability for damage arising in connection with conducting a clinical trial create a legal mechanism of liability and illegality of the act under the Polish Act of March 9, 2023 on clinical trials of medicinal products for human use (Journal of Laws, item 605).
Given the current medical standards, the birth of a new medicinal product (drug) can only become a fact as part of a long-term and expensive research and development process. Such a process carries a high risk of failure. Typically, the research and development process takes many years and its effectiveness is low. However, such research is undoubtedly needed.
“Medical Cannabis in Poland” – this is the topic of the presentation for the “Food, Agriculture, and Cannabis Committee” meeting of ABA on 15th February 2024.
